全文获取类型
收费全文 | 327020篇 |
免费 | 20274篇 |
国内免费 | 1747篇 |
专业分类
耳鼻咽喉 | 4591篇 |
儿科学 | 10841篇 |
妇产科学 | 10798篇 |
基础医学 | 48767篇 |
口腔科学 | 8035篇 |
临床医学 | 27493篇 |
内科学 | 60963篇 |
皮肤病学 | 7017篇 |
神经病学 | 23079篇 |
特种医学 | 12634篇 |
外国民族医学 | 56篇 |
外科学 | 50640篇 |
综合类 | 11770篇 |
现状与发展 | 5篇 |
一般理论 | 178篇 |
预防医学 | 21783篇 |
眼科学 | 8077篇 |
药学 | 23404篇 |
19篇 | |
中国医学 | 1871篇 |
肿瘤学 | 17020篇 |
出版年
2021年 | 3572篇 |
2019年 | 3194篇 |
2018年 | 4685篇 |
2017年 | 3595篇 |
2016年 | 4021篇 |
2015年 | 4718篇 |
2014年 | 6107篇 |
2013年 | 8660篇 |
2012年 | 11316篇 |
2011年 | 11756篇 |
2010年 | 7448篇 |
2009年 | 6639篇 |
2008年 | 10289篇 |
2007年 | 11166篇 |
2006年 | 10963篇 |
2005年 | 10560篇 |
2004年 | 9831篇 |
2003年 | 9172篇 |
2002年 | 8658篇 |
2001年 | 14081篇 |
2000年 | 14426篇 |
1999年 | 12170篇 |
1998年 | 3447篇 |
1997年 | 3147篇 |
1996年 | 2901篇 |
1995年 | 2832篇 |
1994年 | 2571篇 |
1992年 | 8602篇 |
1991年 | 8724篇 |
1990年 | 8529篇 |
1989年 | 8320篇 |
1988年 | 7522篇 |
1987年 | 7263篇 |
1986年 | 6901篇 |
1985年 | 6660篇 |
1984年 | 4861篇 |
1983年 | 4187篇 |
1982年 | 2515篇 |
1979年 | 4499篇 |
1978年 | 3278篇 |
1977年 | 2781篇 |
1976年 | 2547篇 |
1975年 | 2871篇 |
1974年 | 3412篇 |
1973年 | 3419篇 |
1972年 | 3177篇 |
1971年 | 2985篇 |
1970年 | 2876篇 |
1969年 | 2620篇 |
1968年 | 2559篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
3.
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
6.
Feng Wang Dachuan Wang Bingyi Tan Jun Dong Rongjie Feng Zenong Yuan Naiguo Wang 《Medicine》2015,94(39)
The present study aimed at examining the curative effect of modified posterior operation on treatment of Kümmell''s disease.About 30 patients of Kümmell''s disease with complete image and clinical data treated during June 2004 to July 2013 were conducted with anterior and posterior approaches, respectively. Kyphotic Cobb angle, fractured vertebra wedge angle, and the anterior and posterior heights of fractured vertebra were all measured through x-ray before and after operation, and the pain visual analog scale (VAS) was determined for evaluating the effect of operations. The injury and restoration of neurological function were assessed using Frankel classification.Patients in group A were treated with anterior operation, whereas group B was posterior operation. Postoperatively, VAS score, kyphotic Cobb angle, anterior vertebra height, and pathologic vertebra wedge angle were all significantly improved in patients with Kümmell''s disease receiving modified posterior operation (group B). Similar results were also observed in patients with anterior operation. The improvement of VAS and correction rate of kyphotic Cobb angle indicated equivalent effects of posterior and anterior operations. Meanwhile, alleviated neurological function damage was observed in 2 groups. Relevant factor analysis illustrated that there was no significant correlation of the severity and improvement rate of pain symptoms with age, medical history, anterior and posterior vertebra heights, kyphotic Cobb angle, and pathological vertebra wedge angle.Compared with traditional anterior approach, modified posterior operation, adopting transpedicular vertebral body grafting combined with vertebral pedicle screw fixation, could produce equivalent effects on kyphosis correction, pain relief, and improvement of neurological function in patients with Kümmell''s disease. 相似文献
7.
8.
9.
10.